Zylox-Tonbridge Proposes 2025 Final Dividend and Sets Key Dates

Zylox-Tonbridge Medical Technology Co., Ltd. Class H ( (HK:2190) ) just unveiled an update.

Zylox-Tonbridge Medical Technology Co., Ltd. has proposed a final cash dividend of RMB0.22 per share for the financial year ended 31 December 2025, amounting to approximately RMB74.2 million and representing about 30% of the profit attributable to equity shareholders. The dividend, subject to approval at the 2025 annual general meeting, will be paid in renminbi for domestic shares and certain H shares and in Hong Kong dollars for other H shares, with a record date of 2 June 2026 and an expected distribution on or before 18 June 2026.

To determine eligibility for the payout, the company will close its H share register from 29 May to 2 June 2026, during which time no share transfers will be processed. H shares held as treasury shares will not qualify for the dividend, and detailed arrangements and related AGM resolutions will be set out in a forthcoming circular to shareholders, underscoring the company’s continued commitment to returning profits to investors.

The most recent analyst rating on (HK:2190) stock is a Hold with a HK$28.00 price target. To see the full list of analyst forecasts on Zylox-Tonbridge Medical Technology Co., Ltd. Class H stock, see the HK:2190 Stock Forecast page.

More about Zylox-Tonbridge Medical Technology Co., Ltd. Class H

Zylox-Tonbridge Medical Technology Co., Ltd. is a medical technology company incorporated in the People’s Republic of China and listed in Hong Kong. The company issues both domestic shares and H shares, operating within the healthcare sector with a focus on medical devices and related technologies for the Chinese and international markets.

Average Trading Volume: 700,433

Technical Sentiment Signal: Buy

Current Market Cap: HK$7.31B

For detailed information about 2190 stock, go to TipRanks’ Stock Analysis page.